

## AMENDMENTS TO THE CLAIMS

Claims 1-31 (PREVIOUSLY CANCELLED).

32. (AMENDED) A ~~precursor composition~~ system for forming a biologically active anatomical occlusion in an anatomical cavity, comprising:

- a) a polymer-forming, or dissolved polymeric, biodegradable material; ~~and~~,
- b) a biologically active component; and,
- c) a mechanical occlusive device;

wherein component a) is present in an amount of about 5 to 50% by weight based on the overall precursor composition; wherein said precursor composition forms a biologically active, polymeric occlusion mass when introduced into an anatomical cavity; and wherein the polymer has a molecular weight ( $MW_w$ ) of at least 10,000 and less than about 500,000.

33. (AMENDED) The ~~precursor composition~~ system of claim 32, wherein the polymer has a molecular weight of at least about 50,000 and less than about 100,000.

34. (AMENDED) The ~~precursor composition~~ system of claim 32, wherein the polymer is a biodegradable polyester.

35. (AMENDED) The ~~precursor composition~~ system of claim 34, wherein the biodegradable polyester is selected from the group consisting of polyglycolic acids, polylactic acids, polycaprolactones, and their copolymers.

36. (AMENDED) The ~~precursor composition~~ system of claim 32, wherein the polymer is selected from the group consisting of polyhydroxybutyrate, polyhydroxyvalerate, and their copolymers.

37. (AMENDED) The ~~precursor composition~~ system of claim 32, wherein the polymer is a copolymer of trimethylene and a polyanhydride.

38. (AMENDED) The ~~precursor composition~~ system of claim 32, further comprising a water-soluble solvent.

39. (AMENDED) The ~~precursor composition~~ system of claim 38, wherein the solvent is a mixture of ethanol and water.

40. (AMENDED) The ~~precursor composition~~ system of claim 32, wherein the biologically active component has the effect of increasing cell attachment or thrombogenicity.

41. (AMENDED) The ~~precursor composition~~ system of claim 40, wherein the biologically active component is selected from the group consisting of collagen, fibrinogen, vitronectin, other plasma proteins, growth factors, synthetic peptides of these and other proteins having RGD (arginine-glycine-aspartic acid) residues at one or both termini, other cell adhesion peptides, GRGDY, oligonucleotides, full or partial DNA constructs, natural or synthetic phospholipids, or polymers with phosphorylcholine functionality.

42. (WITHDRAWN) The precursor composition of claim 32, wherein the biologically active component is a polynucleotide encoding a peptide involved in wound healing or promoting cellular attachment.

43. (AMENDED) The ~~precursor composition~~ system of claim 32, wherein the biologically active component is selected from the group consisting of fibronectin, laminin, bitronectin, hyaluronic acid, silk-elastin, elastin, fibrinogen, and other basement membrane proteins.

44. (AMENDED) The ~~precursor composition~~ system of claim 32, wherein the biologically active component is pharmaceutically active and is selected from the group

consisting of compounds, proteins, oligonucleotides, ribozymes, anti-sense genes, DSN compacting agents, gene/vector systems, nucleic acids, and viral, liposomes and cationic polymers.

45. (WITHDRAWN) The precursor composition of claim 32, wherein the biologically active component is DNA or RNA sequence having a therapeutic effect after being taken up by a cell.

46. (AMENDED) The precursor composition system of claim 32, wherein the biologically active component is selected from the group consisting of therapeutic polypeptides or proteins, and DNA encoding therapeutic polypeptides and proteins.

47. (WITHDRAWN) The precursor composition of claim 32, wherein the biologically active component is recombinant nucleic acid comprising a viral vector having linked thereto an exogenous nucleic acid sequence.

48. (WITHDRAWN) The precursor composition of claim 47, wherein the viral vector is an adenoviral vector.

49. (WITHDRAWN) The precursor composition of claim 47, wherein the concentration of the viral vector is at least about  $10^{10}$  plaque-forming units (PFU).

50. (WITHDRAWN) The precursor composition of claim 48, wherein the concentration of the viral vector is at least about  $10^{10}$  PFU.

51. (WITHDRAWN) The precursor composition of claim 49, wherein the concentration of the viral vector is at least about  $10^{11}$  PFU.

52. (WITHDRAWN) The precursor composition of claim 50, wherein the concentration of the viral vector is at least about  $10^{11}$  PFU.

53. (AMENDED) A biologically active occlusion mass formed from the precursor composition using the system of claim 32.

54. (AMENDED) A procedure for at least partially filling an anatomical cavity comprising the steps of:

- a) introducing the precursor composition system of claim 32 into said cavity; and
- b) forming a biologically active occlusive mass in the cavity.

55. (AMENDED) The procedure of claim 54, wherein ~~a bolus of the precursor material is introduced into a catheter and injected into the cavity~~ the mechanical occlusive device of claim 32 is first introduced into the anatomical cavity by means of a catheter followed by introduction of a bolus of the polymer-forming or dissolved polymeric, biodegradable material into the anatomical cavity, the bolus being introduced by means of the same or a different catheter, ~~precursor material is introduced into a catheter and injected into the cavity,~~ and once the mass is formed, the catheter is removed.

56. (AMENDED) The procedure of claim 55, wherein prior to and during injection into the anatomical cavity, the bolus of ~~precursor composition~~ polymer-forming or dissolved polymeric, biodegradable material is separated from any blood that may have refluxed into the distal end of the catheter by a plug of barrier solvent suitable for such separation.

57. (AMENDED) The procedure of claim 56, wherein the barrier solvent is a 20 – 30% aqueous ethanol solution.

58. (CANCELLED)

59. (AMENDED) A kit for at least partially filling an anatomical cavity comprising the following parts:

- a) the system of claim 32; and,
- b) one or more suitable catheters for delivery of the ~~precursor composition~~ polymer-forming, or dissolved polymeric, biodegradable material, the biologically active compound and the mechanical occlusive device into the anatomical cavity.

60. (CANCELLED)